Scarica l'app Stockscreener
174.38
176.97%
111.42
Pre-mercato:
160.17
-14.21
-8.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$62.96
Aprire:
$116.02
Volume 24 ore:
193.10M
Relative Volume:
20.61
Capitalizzazione di mercato:
$69.62B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-21.41
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+173.88%
1M Prestazione:
+182.08%
6M Prestazione:
+250.87%
1 anno Prestazione:
+524.79%
Intervallo 1D:
$114.46
$176.66
Intervallo di 1 settimana:
$60.82
$176.66
Portata 52W:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Why Moderna Stock’s Historic Surge Is a Big Lesson for Markets and 5 Other Things to Know Today - Barron's
Jefferies Adjusts Price Target on Moderna to $150 From $60, Keeps Hold Rating - marketscreener.com
Moderna and Merck revive mRNA hopes with melanoma success - chinadailyasia.com
Moderna shares slide as investors lock in gains after historic cancer vaccine rally - Yahoo Finance
Moderna's Cancer Vaccine Breakthrough: Why AI Healthcare Is Being Repriced - Moomoo
mRNA cancer vaccine succeeds in Phase III trial; Moderna surges 177% in a day, igniting global vaccine sector - finance.biggo.com
Moderna breakthrough: The options lottery tickets that paid out - Seeking Alpha
Will Moderna Wake Up the Health Care Sector? - marketscreener.com
Moderna dips 15% premarket after historic rally - Breakingthenews.net
E Fund Management Co. Ltd. Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
$Moderna (MRNA.US)$ - Moomoo
Edmond DE Rothschild Holding S.A. Takes Position in Moderna, Inc. $MRNA - MarketBeat
Analyst recommendations: Datadog, Merck, Estee Lauder, Moderna, Target… - marketscreener.com
Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead (MRNA:NASDAQ) - Seeking Alpha
5,814 Shares in Moderna, Inc. $MRNA Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
After Moderna, How to Spot the Next Short Squeeze on moomoo - Moomoo
Moderna and Merck & Co are the stocks of the day on Wall Street - marketscreener.com
BlackRock Inc. Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Zacks Investment Ideas feature highlights: Moderna and Merck's - Yahoo Finance Singapore
Moderna says melanoma vaccine trial shows "landmark moment" in treatment - CBS News
Moderna and Merck shares soar on mRNA cancer vaccine - Axios
Moderna pins hopes on mRNA ‘game-changer’ for cancer vaccines - ft.com
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - Yahoo Finance
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine WinModerna (NASDAQ:MRNA) - Benzinga
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough - Yahoo Finance
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough - Stocktwits
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks TodayModerna (NASDAQ:MRNA) - Benzinga
Moderna's Most-Traded Call Options Up 54,000,000% on Cancer Vaccine Success | Options Income Daily - Moomoo
Moderna and Merck Revive mRNA Hopes With Melanoma Success - Moomoo
Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer - CBS News
EXPERT REACTION: Moderna announce results of Phase 3 trial of personalized mRNA cancer vaccine - Scimex
US stock futures steady after tech slump; investors focus on Middle East tensions - Yahoo Finance
Cancer vaccine shows promise in late-stage melanoma trial - NewsNation
Why Moderna Stock Skyrocketed Today - The Motley Fool
Moderna stock surges as melanoma vaccine trial shows "landmark moment" - Yahoo Finance
Wall Street rises as yields ease, Moderna lifts healthcare stocks - Virginia Business
Wall St rises as yields ease, Moderna lifts healthcare stocks - marketscreener.com
Moderna’s skin cancer vaccine shows promise in trial - Semafor
Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial - ABC7 Bay Area
Moderna reaches "landmark moment" in Melanoma vaccine trial - CBS News
Moderna says its experimental vaccine prevented melanoma from returning or spreading - CBS News
Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations - Yahoo Finance
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In FocusMerck & Co (NYSE:MRK) - Benzinga
Moderna Stock Soars on Cancer Vaccine Success - WSJ
Moderna vaccine shows promise in reducing melanoma recurrence - CBS News
Opinion | Moderna’s Road to a Cancer Vaccine - WSJ
Moderna Surges as Stocks Rise & Long-Term Yields Retreat | Closing Bell - marketscreener.com
Moderna Stock: The Cancer Vaccine Breakthrough Behind the Surge - Barron's
Moderna (MRNA) Soars 176.97% Following Promising Cancer Vaccine Trial Results - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.02%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):